Table I.
Patient demographics: histology, age, sex, and treatment.
| Patient | Histology | Age | Sex | Cycles UCN/Flu |
Days Flu |
Response to UCN/Flu |
Prior therapy and response |
|---|---|---|---|---|---|---|---|
| 1 | CLL | 49 | M | 4 | 1 | SD | Fludarabine PR, chlorambucil PD |
| 2 | CLL | 59 | M | 2 | 2 | PD | Fludarabine PR, CVP PR, CVP SD, 506U78 PD |
| 3 | Lymphoplasmacytic lymphoma | 55 | M | 3 | 3/4 | PD | 2CDA?, rituximab PD, mitoxantrone/fludarabine PD; rituximab PD, Dex/Adria/Vcr PD |
| 4 | Follicular lymphoma | 48 | M | 7 | 5 | PR | EPOCH PR |
| 5 | CLL | 51 | M | 3 | 5 | PR | Pred/Vcr/Mitox/Cytox SD, carboplatin SD; Dex/Vcr/ Bleo/Etop/Ara-C/carboplatin SD; fludarabine X2 SD, BL22? |
| 6 | CLL | 59 | M | 3 | 5 | SD | Fludarabine X 7 PR, rituximab NE, fludarabine PR |
| 7 | Follicular lymphoma | 66 | F | 4 | 5 | PR | ProMACE/CytaBOM PR; Dex/mitoxantrone/ fludarabine PR; rituximab NE, ESHAP PD; EPOCH?, methotrexate/Etop/Ifos SD |
| 8 | Follicular lymphoma | 75 | M | 2 | 5 | PR | CHOP CR, fludarabine PR, rituximab PR |
| 9 | Transformed follicular | 66 | F | 1 | 0 | PD | CVP PD, CHOP X 2?, CVP/rituximab PD, XRT |
| 10 | CLL | 48 | M | 1 | 0 | SD | Fludarabine PD, CVP?, rituximab PD |
| 11 | Follicular lymphoma | 54 | M | 3 | 5 | PR | ProMACE/CytaBOM PR |
| 12 | Mantle cell lymphoma | 57 | F | 1 | 0 | PD | EPOCH-rituximab/vaccine CR |
| 13 | Follicular lymphoma | 43 | M | 3 | 5 | SD | ProMACE PR; idiotype vaccine PD, CVP PD; rituximab X2 PR, rituximab PD, fludarabine PR |
| 14 | SLL | 58 | M | 1 | 0 | PR | CHOP/Rituxan PR, mitoxantrone/fludarabine?; BEAM?, rituximab PR, dexamethasone SD; mitoxantrone/fludarabine SD; rituximab/ apolizumab CR, ABMT PR |
| 15 | CLL | 57 | M | 2 | 5 | SD | Prednisone/fludarabine CR, rituximab PR, CVP SD |
| 16 | CLL | 51 | M | 7 | 5 | SD | Fludarabine/Cytoxan CR, Campath SD, CHOP MR; rituximab X 2 SD, Cytoxan/fludarabine SD, rituximab SD; Cytoxan/fludarabine/rituximab SD, rituximab SD |
| 17 | CLL | 70 | F | 6 | 5 | CR | Fludarabine PR, dexamethasone SD; Cytoxan/ fludarabine/rituximab?, chlorambucil SD |
| 18 | Mantle cell lymphoma | 55 | M | 3 | 5 | SD | CHOP PR, ICE SD, XRT CR |
CLL, chronic lymphocytic leukemia; UCN, 7-hydroxystaurosporine; Flu, fludararbine monophosphate; SD, stable disease; PD, progressive disease; PR, partial response; CR, complete response; CVP, cyclophosphamide, vincrisitne, prednisone; 2CDA, cladribine; Dex, dexamethasone; Vcr, vincristine; EPOCH, etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone; Pred, prednisone; Mitox, mitoxantrone; Cytox, Cytoxan; Bleo, bleomycin; Etop, etoposide; Ara-C, cytarabine; ProMACE, prednisone, methotrexate, doxorubicin, cyclophosphamide, and etopside; CytaBOM, cytarabine, bleomycin, vincristine, methotrexate; ESHAP, etoposide, methylprednisolone, high-dose cytarabine, cisplatin; Ifos, ifosfamide; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; XRT, X-radiotherapy; BEAM, carmustine, etoposide, cytarabine, melphalan; ABMT, autologous bone marrow transplant; MR, mixed response; ICE, ifosfamide, carboplatin, etoposide.